Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.

Josep M. Piulats,Luis de la Cruz-Merino,María Teresa Curiel García,Alfonso Berrocal,Lorenzo Alonso Carrión,Enrique Espinosa,Rafael López Castro,Delvys Rodriguez Abreu,Pablo Luna Fra,Salvador Martin Algarra

Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.

2017

Josep M. Piulats
Luis de la Cruz-Merino
María Teresa Curiel García
Alfonso Berrocal
Lorenzo Alonso Carrión
Enrique Espinosa
Rafael López Castro
Delvys Rodriguez Abreu
Pablo Luna Fra
Salvador Martin Algarra

9533Background: Uveal melanoma is the most common primary intraocular malignant tumor in adults. Overall Survival (OS) at 5 years(y) is 62% due high incidence of liver metastasis, fatal within 4-9 ...

Keywords:

Melanoma
Nivolumab
Ipilimumab
Physical therapy
Cancer research
Medicine
Metastasis
Oncology
first line
Cancer
Internal medicine
open label study
Pathology
adult patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations